Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Shenwei Ningyu is a Traditional Chinese Medicine (TCM) formulation developed by Guangdong Laida Pharmaceutical for the treatment of major depressive disorder (MDD). It is specifically indicated for patients diagnosed with the "Qi and Yin deficiency" syndrome (气阴两虚证) according to TCM principles. The drug is currently in Phase III clinical development in China, with studies such as CTR20171668 evaluating its efficacy and safety in this patient population. As a botanical product, it likely utilizes a multi-target approach characteristic of herbal medicine to alleviate depressive symptoms and restore physiological balance.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Shenwei Ningyu.